相关临床试验
1636
100 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1701
Unknown
5
0.3%
已完成
1097
67.0%
Enrolling By Invitation
11
0.7%
尚未招募
32
2.0%
No Longer Available
1
0.1%
终止
144
8.8%
招募中
174
10.6%
暂停
7
0.4%
撤回
108
6.6%
进行中（未招募）
57
3.5%
暂无批准数据
- Yale researchers discovered that B-cell acute lymphoblastic leukemia cells have a unique vulnerability to β-catenin accumulation, unlike other cancers that typically have high β-catenin levels. - The study found that GSK3β inhibitors, originally developed for Alzheimer's and Parkinson's diseases, effectively kill B-ALL cells by disrupting their β-catenin clearance mechanism. - Patient-derived xenograft models showed that GSK3β inhibitors overcame conventional drug resistance and eradicated B-ALL cells at lower concentrations than previously tested doses. - The findings provide a rationale for repurposing existing GSK3β inhibitors for patients with refractory B-cell malignancies, particularly those who have relapsed.
- A new study published in BMJ Medicine found that only 45% of Medicare beneficiaries who received FDA accelerated approval cancer drugs were treated with medications that ultimately improved survival. - Between 2012 and 2020, 178,000 Medicare beneficiaries accessed early cancer treatments through the accelerated pathway, generating 76,000 additional life-years at an average cost of $263,000 per year. - Medicare spent over $20 billion more on accelerated approval drugs compared to alternative treatments, with costs ranging from $26,000 per life-year for melanoma drugs to $4.5 million for some breast cancer treatments. - Just three drugs for melanoma and lung cancer accounted for over two-thirds of all survival benefits, highlighting the concentrated nature of therapeutic gains from the program.
- The FDA has approved UPLIZNA (inebilizumab-cdon) for treating generalized myasthenia gravis in adults with anti-AChR or anti-MuSK antibodies, marking the first CD19-targeted B cell therapy for this indication. - In the Phase 3 MINT trial, UPLIZNA demonstrated significant symptom improvement with a 1.9-point difference in MG-ADL scores compared to placebo at 26 weeks (p<0.0001). - The therapy offers convenient twice-yearly dosing after initial loading doses and allows for steroid tapering, with 87.4% of patients reducing steroid doses to 5 mg or less daily. - This represents the third FDA-approved indication for UPLIZNA, expanding treatment options for the estimated 80,000-100,000 Americans living with myasthenia gravis.
- Faron Pharmaceuticals announced the Phase II BEAM-X trial evaluating bexmarilimab plus azacitidine in AML patients with measurable residual disease after stem cell transplantation, targeting a critical unmet need in preventing relapse. - Updated BEXMAB study data presented at ASH 2025 showed median overall survival of 14.5 months in relapsed/refractory HR-MDS patients, significantly improving upon the historical 5-6 month survival rate. - The combination achieved remarkable 70% complete remission rates in treatment-naïve HR-MDS patients with TP53 mutations, with 50% proceeding to potentially curative stem cell transplant. - Bexmarilimab demonstrated restoration of healthy bone marrow function, with 57% of transfusion-dependent frontline patients achieving transfusion independence.
- Google DeepMind and Yale University unveiled C2S-Scale 27B, a 27-billion-parameter AI foundation model that successfully generated and experimentally validated a novel hypothesis for cancer treatment. - The AI identified that combining silmitasertib (CX-4945) with low-dose interferon increases antigen presentation by 50 percent, potentially making "cold" tumors visible to the immune system. - Laboratory validation confirmed the AI's prediction using human neuroendocrine cell models, demonstrating the model's ability to reason through complex biological contexts rather than simply processing data. - The discovery represents a potential breakthrough for treating immunotherapy-resistant tumors and showcases how large-scale AI can generate entirely new therapeutic hypotheses for experimental validation.
- Bexorg completed a $23 million Series A financing led by Engine Ventures, bringing total funding to $42.5 million to advance its integrated AI and whole-human brain platform for CNS drug development. - The company's platform addresses the 95% clinical trial failure rate in CNS drug development by using comprehensive human brain datasets instead of traditional cellular and animal models. - Bexorg has established one of the world's largest repositories of human CNS data, spanning hundreds of whole-brain experiments across Alzheimer's, Parkinson's, and other neurodegenerative conditions. - The funding will accelerate strategic partnerships and internal CNS programs while expanding the AI engine trained on clinically predictive whole-human brain data.
- Nilo Therapeutics launched with $101 million Series A financing led by The Column Group, DCVC Bio, and Lux Capital to develop a new class of medicines targeting neural circuits in immune diseases. - The company is pioneering a differentiated approach to immunomodulation by targeting specific vagal neurons that regulate systemic immune activation and inflammation, moving beyond conventional immunosuppression. - Founded by world-leading scientists from Columbia, Yale, and Harvard universities, Nilo appointed Kim Seth as CEO to lead the transition from stealth mode and advance preclinical programs. - The therapeutic approach aims to modulate multiple immune pathways simultaneously by targeting "master regulator" brain-body circuits, potentially reducing therapeutic resistance across autoimmune and inflammatory diseases.
- CND Life Sciences received FDA Breakthrough Device Designation for its Syn-One Test, a skin biopsy diagnostic tool that demonstrates 95.5% sensitivity in detecting abnormal synuclein in patients with synuclein-associated diseases. - The company was awarded a $3 million NIH grant to conduct a three-year multicenter study investigating whether the Syn-One Test can predict Parkinson's disease risk in essential tremor patients. - A Yale University study showed the Syn-One Test changed diagnosis in 52% of cases and medical management in 60% of 149 evaluable patients, demonstrating significant clinical utility. - The diagnostic test uses proprietary immunofluorescence techniques to detect phosphorylated alpha-synuclein in cutaneous nerves through a simple in-office skin biopsy procedure.
- Achieve Life Sciences has named Dr. Mark Rubinstein as Interim Chief Medical Officer, succeeding Dr. Cindy Jacobs as the company advances its smoking cessation drug cytisinicline. - The FDA recently accepted the company's New Drug Application for cytisinicline with a PDUFA completion date of June 20, 2026, targeting the estimated 15 million American adults who attempt to quit smoking annually. - Cytisinicline has received FDA Breakthrough Therapy designation for e-cigarette cessation, addressing an unmet medical need with no currently approved treatments for vaping cessation. - The plant-derived alkaloid works by binding to nicotinic acetylcholine receptors to reduce nicotine cravings and the rewarding effects of tobacco products.
- Apple's new hypertension notification feature for Apple Watch Series 9 and later models has received FDA approval and will launch with watchOS 26 on September 15. - The feature uses optical heart sensor data to analyze blood vessel responses over 30-day periods, with Apple claiming it could identify more than one million previously undiagnosed hypertension cases within the first year. - Users receiving hypertension alerts will be prompted to conduct seven-day home blood pressure monitoring with upper-arm cuffs and share results with healthcare providers. - The algorithm was trained on data from over 100,000 participants and validated in a clinical study of more than 2,000 people, though detailed performance metrics remain to be disclosed.
